Orthocell has been featured in a special report on Stockhead highlighting Orthocell’s consistent growth in sales of our regenerative medicine products, Striate+ and Remplir.
An excerpt:
“𝘛𝘩𝘦 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘦𝘴𝘵𝘪𝘮𝘢𝘵𝘦𝘴 𝘵𝘩𝘦 𝘨𝘭𝘰𝘣𝘢𝘭 𝘮𝘢𝘳𝘬𝘦𝘵 𝘰𝘱𝘱𝘰𝘳𝘵𝘶𝘯𝘪𝘵𝘺 𝘧𝘰𝘳 𝘚𝘵𝘳𝘪𝘢𝘵𝘦+ 𝘢𝘯𝘥 𝘙𝘦𝘮𝘱𝘭𝘪𝘳 𝘪𝘯 𝘯𝘪𝘯𝘦 𝘬𝘦𝘺 𝘫𝘶𝘳𝘪𝘴𝘥𝘪𝘤𝘵𝘪𝘰𝘯𝘴 – 𝘪𝘯𝘤𝘭𝘶𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘜𝘚, 𝘌𝘶𝘳𝘰𝘱𝘦, 𝘜𝘒, 𝘈𝘶𝘴𝘵𝘳𝘢𝘭𝘪𝘢/𝘕𝘦𝘸 𝘡𝘦𝘢𝘭𝘢𝘯𝘥, 𝘚𝘪𝘯𝘨𝘢𝘱𝘰𝘳𝘦, 𝘊𝘢𝘯𝘢𝘥𝘢, 𝘉𝘳𝘢𝘻𝘪𝘭, 𝘑𝘢𝘱𝘢𝘯 𝘢𝘯𝘥 𝘛𝘩𝘢𝘪𝘭𝘢𝘯𝘥 – 𝘵𝘰 𝘣𝘦 𝘜𝘚$4.5 𝘣𝘪𝘭𝘭𝘪𝘰𝘯. 𝘖𝘳𝘵𝘩𝘰𝘤𝘦𝘭𝘭 𝘴𝘢𝘪𝘥 𝘦𝘹𝘱𝘢𝘯𝘴𝘪𝘰𝘯 𝘪𝘯𝘵𝘰 𝘰𝘵𝘩𝘦𝘳 𝘮𝘢𝘳𝘬𝘦𝘵𝘴 𝘸𝘰𝘶𝘭𝘥 𝘴𝘦𝘦 𝘢𝘯 𝘪𝘯𝘤𝘳𝘦𝘢𝘴𝘦 𝘪𝘯 𝘵𝘩𝘦𝘴𝘦 𝘱𝘳𝘰𝘫𝘦𝘤𝘵𝘪𝘰𝘯𝘴, 𝘥𝘦𝘮𝘰𝘯𝘴𝘵𝘳𝘢𝘵𝘪𝘯𝘨 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵 𝘨𝘳𝘰𝘸𝘵𝘩 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘪𝘯 𝘵𝘩𝘦 𝘪𝘮𝘮𝘦𝘥𝘪𝘢𝘵𝘦 𝘧𝘶𝘵𝘶𝘳𝘦.”